Pure Global
NCT06337110

A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men

Interventional, Open-label, Single-dose Trial Investigating the Absorption, Metabolism, and Excretion (AME) of Lu AF28996 Following a Single Oral Dosing of 14C-Lu AF28996 to Healthy Men
H. Lundbeck A/S·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
Lu AF28996
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
H. Lundbeck A/S
Location
Leeds, United Kingdom
Timeline & enrollment
Phase
Phase 1
Start date
Apr 10, 2024
End date
May 25, 2024
Enrollment
8 participants
Primary outcome

Total Recovery of the Administered Radiolabelled Drug-related Material (Percentage of Dose in Urine and Faeces),AUC0-infinity: Area Under the Plasma Concentration Curve of Radiolabelled Drug-related Material from Zero to Infinity,Cmax: Maximum Observed Plasma Concentration of Radiolabelled Drug-related Material,Tmax: Nominal Time Corresponding to the Occurrence of Cmax of Radiolabelled Drug-related Material,T½: Apparent Elimination Half-life of Radiolabelled Drug-related Material,AUC0-infinity of Lu AF28996,Cmax of Lu AF28996,Tmax of Lu AF28996,T½ of Lu AF28996

Summary

The main goal of this study is to learn about how Lu AF28996 moves into, through, and out of
 the body after a single dose is given to healthy male participants.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06337110
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06337110 through Pure Global AI's free database. This Phase 1 trial is sponsored by H. Lundbeck A/S and is currently Recruiting. The study focuses on Healthy Participants. Target enrollment is 8 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.